Petty G W, Lennihan L, Mohr J P, Hauser W A, Weitz J, Owen J, Towey C
Department of Neurology, Neurological Institute, New York, NY 10032.
Ann Neurol. 1988 Jun;23(6):570-4. doi: 10.1002/ana.410230607.
We used life-table techniques to determine risks of morbidity and mortality associated with long-term warfarin treatment in an anticoagulation clinic. Cumulative risks for life-threatening complications and warfarin-related death among all patients were 1% at 6 months, 5% at 1 year, and 7% at 2 and 3 years. Cox regression analysis using age as a continuous variable failed to show an effect of age on cumulative risks of complication. The occurrence of a minor complication during the course of therapy did not place patients at higher risk for developing a major complication that would prompt discontinuation of therapy or cause death. There was no statistically significant difference between the cumulative risks of patients anticoagulated for cerebrovascular disease and the cumulative risks of patients anticoagulated for other indications.
我们运用生命表技术来确定在抗凝门诊接受长期华法林治疗所伴随的发病和死亡风险。所有患者中，危及生命并发症和华法林相关死亡的累积风险在6个月时为1%，1年时为5%，2年和3年时为7%。将年龄作为连续变量进行Cox回归分析，未显示年龄对并发症累积风险有影响。治疗过程中出现轻微并发症并不会使患者发生严重并发症的风险增加，严重并发症会促使治疗中断或导致死亡。因脑血管疾病接受抗凝治疗的患者累积风险与因其他适应症接受抗凝治疗的患者累积风险之间无统计学显著差异。
